Ustekinumab
Copyright policy )Ustekinumab
Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody currently undergoing US Food and Drug Administration review for use as a psoriasis treatment. The candidate has also been evaluated in Phase 2 studies as a treatment for psoriatic arthritis, Crohn disease and multiple sclerosis.In large clinical trials, ustekinumab has proven effective for treating moderate to severe plaque psoriasis. Although long-term follow-up studies are needed to address safety concerns, the hopes are high for psoriasis treatment. Ustekinumab has recently been approved for marketing in Canada and Europe.
- Tufts University United States
Canada, Clinical Trials as Topic, Arthritis, Psoriatic, NF-kappa B, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, United States, Europe, Crohn Disease, NF-KappaB Inhibitor alpha, Animals, Humans, I-kappa B Proteins, Ustekinumab, Drug Approval
Canada, Clinical Trials as Topic, Arthritis, Psoriatic, NF-kappa B, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, United States, Europe, Crohn Disease, NF-KappaB Inhibitor alpha, Animals, Humans, I-kappa B Proteins, Ustekinumab, Drug Approval
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).57 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!